These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 30772756)

  • 1. Therapeutic approaches to treat human spliceosomal diseases.
    DeNicola AB; Tang Y
    Curr Opin Biotechnol; 2019 Dec; 60():72-81. PubMed ID: 30772756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches.
    Armstrong RN; Steeples V; Singh S; Sanchi A; Boultwood J; Pellagatti A
    Adv Biol Regul; 2018 Jan; 67():13-29. PubMed ID: 28986033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
    Pellagatti A; Boultwood J
    Adv Biol Regul; 2017 Jan; 63():59-70. PubMed ID: 27639445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Splicing Factor Mutations on Pre-mRNA Splicing in the Myelodysplastic Syndromes.
    Yip BH; Dolatshad H; Roy S; Pellagatti A; Boultwood J
    Curr Pharm Des; 2016; 22(16):2333-44. PubMed ID: 26916023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors.
    Scott LM; Rebel VI
    J Natl Cancer Inst; 2013 Oct; 105(20):1540-9. PubMed ID: 24052622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders.
    Visconte V; Makishima H; Maciejewski JP; Tiu RV
    Leukemia; 2012 Dec; 26(12):2447-54. PubMed ID: 22678168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [RNA splicing dysregulation in hematological malignancies].
    Yoshida M; Yamauchi H; Sakumoto M; Yoshimi A
    Rinsho Ketsueki; 2023; 64(7):646-653. PubMed ID: 37544725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3' splice sites within RNA secondary structures.
    Kesarwani AK; Ramirez O; Gupta AK; Yang X; Murthy T; Minella AC; Pillai MM
    Oncogene; 2017 Feb; 36(8):1123-1133. PubMed ID: 27524419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Splicing Factor Mutations in Cancer.
    Bejar R
    Adv Exp Med Biol; 2016; 907():215-28. PubMed ID: 27256388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pan-cancer analysis identifies mutations in
    Liu Z; Zhang J; Sun Y; Perea-Chamblee TE; Manley JL; Rabadan R
    Proc Natl Acad Sci U S A; 2020 May; 117(19):10305-10312. PubMed ID: 32332164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.
    Brierley CK; Steensma DP
    Curr Hematol Malig Rep; 2016 Dec; 11(6):408-415. PubMed ID: 27492253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts.
    Kang MG; Kim HR; Seo BY; Lee JH; Choi SY; Kim SH; Shin JH; Suh SP; Ahn JS; Shin MG
    BMC Cancer; 2015 Jun; 15():484. PubMed ID: 26115659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia.
    Shiozawa Y; Malcovati L; Gallì A; Sato-Otsubo A; Kataoka K; Sato Y; Watatani Y; Suzuki H; Yoshizato T; Yoshida K; Sanada M; Makishima H; Shiraishi Y; Chiba K; Hellström-Lindberg E; Miyano S; Ogawa S; Cazzola M
    Nat Commun; 2018 Sep; 9(1):3649. PubMed ID: 30194306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spliceosomal factor mutations and mis-splicing in MDS.
    Hershberger CE; Daniels NJ; Padgett RA
    Best Pract Res Clin Haematol; 2020 Sep; 33(3):101199. PubMed ID: 33038983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DHX15 is involved in SUGP1-mediated RNA missplicing by mutant SF3B1 in cancer.
    Zhang J; Huang J; Xu K; Xing P; Huang Y; Liu Z; Tong L; Manley JL
    Proc Natl Acad Sci U S A; 2022 Dec; 119(49):e2216712119. PubMed ID: 36459648
    [No Abstract]   [Full Text] [Related]  

  • 16. [Role of Aberrant Splicing in Pathogenesis of Myelodysplastic Syndromes-Review].
    Li L; Xiao ZJ; Sun XM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):617-621. PubMed ID: 28446323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes.
    Nguyen HD; Leong WY; Li W; Reddy PNG; Sullivan JD; Walter MJ; Zou L; Graubert TA
    Cancer Res; 2018 Sep; 78(18):5363-5374. PubMed ID: 30054334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the aberrant splicing of MAP3K7 induced by cancer-associated SF3B1 mutation.
    Li Z; Zhao B; Shi Y; Liang Y; Qian R; Wan Y
    J Biochem; 2021 Sep; 170(1):69-77. PubMed ID: 33751071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the SF3B1-SUGP1 interface reveals how numerous cancer mutations cause mRNA missplicing.
    Zhang J; Xie J; Huang J; Liu X; Xu R; Tholen J; Galej WP; Tong L; Manley JL; Liu Z
    Genes Dev; 2023 Dec; 37(21-24):968-983. PubMed ID: 37977822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SF3b1 mutations associated with myelodysplastic syndromes alter the fidelity of branchsite selection in yeast.
    Carrocci TJ; Zoerner DM; Paulson JC; Hoskins AA
    Nucleic Acids Res; 2017 May; 45(8):4837-4852. PubMed ID: 28062854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.